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Background
Since the advent of combination antiretroviral therapy
(cART), several studies have described an increase in
the incidence of Hodgkin lymphoma (HL). This increase
has been postulated to be linked with immunologic
mechanisms occurring at cART initiation. Relationships
between the CD4 cell count and the risk of HL have
also been investigated. Our study aimed to evaluate the
risk of HL by use of cART and its duration.
Materials and methods
From the French Hospital Database on HIV (FHDH-
ANRS CO4), a large prospective hospital cohort, we stu-
died the incidence of HL in 1992-2007 according to the
duration of cART exposure: no cART and year<1996,
no cART and year ≥1996, [0;1], [1;2], [2;3], [3;6] and ≥6
months. Relative rates (RR) of HL were estimated using
Poisson regression models for the duration of cART
exposure, adjusted for age, period of followup, sex and
exposure group, migration from sub-Saharan Africa,
AIDS stage, and CD4 cell count.
Results
Our study included 286,806 person-years (PY) of fol-
lowup and 187 HL cases. The incidence of HL was not
associated with the period: 0.79, 0.60, and 0.64 per 1000
PY before 1996, in 1996-1999, and since 2000, respec-
t i v e l y( p = 0 . 5 5 ) .R i s ko fH Lw as significantly related to
cART (p=0.008), being especially high during the first
3 months of use (Table 1). The association remained
after adjustment for age, sex and exposure group, migra-
tion, and AIDS stage (p=0.006), but not in the model
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Table 1
No of diagnoses
Incidence per
1000 PY
Crude RR
95%CI
Adjusted RR Model 1*
95%CI
Adjusted Model 2**
95%CI
no cART and year<1996 43 0.58 1.35 [0.84;2.18] 1.14 [0.7;1.85] 0.68 [0.4;1.17]
no cART and year>=1996 28 0.79 1 1 1
[0;1] 6 2.01 3.48 [1.48;8.17] 3.09 [1.31;7.28] 1.75 [0.73;4.19]
[1;2] 2 0.68 1.19 [0.29;4.89] 1.05 [0.25;4.33] 0.30 [0.04;2.23]
[2;3] 7 2.35 4.11 [1.85;9.13] 3.62 [1.62;8.08] 2.17 [0.96;4.92]
[3;6] 8 0.94 1.63 [0.76;3.46] 1.43 [0.67;3.05] 0.90 [0.41;1.94]
≥6 93 0.58 1.00 [0.69;1.43] 0.83 [0.57;1.2] 0.75 [0.51;1.10]
*adjusted for age, sex and exposure group, migration for sub-Saharan Africa, AIDS stage. **adjusted for variables in model 1 and CD4 cell count.
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© 2010 Lanoy et al; licensee BioMed Central Ltd.accounting for CD4 cell count (p=0.058). A peak of HL
incidence was observed for 50-99 CD4 cell count and
the association between risk of HL and CD4 cell count
remained significant in the multivariate model (Figure 1,
p<10
-6).
Conclusion
Our results support that the early cART effect on the
risk of HL is largely explained by CD4 count.
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